As a representative of an industry committed to discovering new cures and ensuring patient access to them, MassBio strongly supports efforts to increase the availability of accurate, scientific evidence to inform clinical decision-making. MassBio believes that individual patients and their doctors should be armed with the best available information to help assess the relative clinical benefits and risks of various treatment alternatives. When appropriately applied, comparative effectiveness information is a valuable tool that, together with a variety of other types of medical evidence, can contribute to improving health care delivery.
MassBio is concerned that comparative effectiveness information may be used strictly as a means to contain costs, rather than deliver health care value by improving patient health outcomes.
We support the BIO Principles on Comparative Effectiveness.
MassBio is a not-for-profit organization committed to advancing Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives.
Founded in 1985, MassBio represents over 650 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, and works to advance policy and promote education, while providing member programs and events, industry information, and services.
- October 2, 2015 Industry officials talk drug costs, disclosure at Mass. biotech caucus: State House News - 10/1/2015
- September 30, 2015 Eight MA Companies Named to Fierce 15
- September 24, 2015 Receptionist
- September 23, 2015 MA Farm, Science, Business Leaders Express Opposition to Food Labeling Bill
- September 22, 2015 MassBio Releases Statement on Secretary Clinton's Healthcare Proposal